ATE440617T1 - Unterdrückung von allergischen reaktionen durch transkutane verabreichung von allergenen zusammen mit oder fusioniert mit toxinuntereinheiten oder deren fragmenten - Google Patents
Unterdrückung von allergischen reaktionen durch transkutane verabreichung von allergenen zusammen mit oder fusioniert mit toxinuntereinheiten oder deren fragmentenInfo
- Publication number
- ATE440617T1 ATE440617T1 AT02751507T AT02751507T ATE440617T1 AT E440617 T1 ATE440617 T1 AT E440617T1 AT 02751507 T AT02751507 T AT 02751507T AT 02751507 T AT02751507 T AT 02751507T AT E440617 T1 ATE440617 T1 AT E440617T1
- Authority
- AT
- Austria
- Prior art keywords
- ctb
- responses
- allergen
- administration
- found
- Prior art date
Links
- 239000013566 allergen Substances 0.000 title abstract 6
- 206010020751 Hypersensitivity Diseases 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 230000001629 suppression Effects 0.000 title 1
- 239000003053 toxin Substances 0.000 title 1
- 231100000765 toxin Toxicity 0.000 title 1
- 230000004044 response Effects 0.000 abstract 4
- 230000005875 antibody response Effects 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- 230000009885 systemic effect Effects 0.000 abstract 2
- 241000699670 Mus sp. Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000000763 evoking effect Effects 0.000 abstract 1
- 229930186900 holotoxin Natural products 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000001165 lymph node Anatomy 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 230000009696 proliferative response Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29314201P | 2001-05-23 | 2001-05-23 | |
| PCT/IB2002/003053 WO2002093998A2 (en) | 2001-05-23 | 2002-05-23 | Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE440617T1 true ATE440617T1 (de) | 2009-09-15 |
Family
ID=23127818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02751507T ATE440617T1 (de) | 2001-05-23 | 2002-05-23 | Unterdrückung von allergischen reaktionen durch transkutane verabreichung von allergenen zusammen mit oder fusioniert mit toxinuntereinheiten oder deren fragmenten |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050074462A1 (de) |
| EP (1) | EP1450855B1 (de) |
| JP (1) | JP4339598B2 (de) |
| AT (1) | ATE440617T1 (de) |
| AU (1) | AU2002339121B2 (de) |
| CA (1) | CA2447795A1 (de) |
| DE (1) | DE60233519D1 (de) |
| DK (1) | DK1450855T3 (de) |
| WO (1) | WO2002093998A2 (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005504002A (ja) * | 2001-02-13 | 2005-02-10 | ガバメント オブ ザ ユナイテッド ステイツ、 アズ リプリゼンティッド バイ ザ セクレタリィ オブ ジ アーミイ | 経皮免疫感作のためのワクチン |
| FR2822049B1 (fr) | 2001-03-13 | 2003-08-01 | Dbv Medica 1 | Patch destine notamment a depister l'etat de sensibilisation d'un sujet a un allergene, procede de fabrication et utilisation |
| US7635488B2 (en) | 2001-03-13 | 2009-12-22 | Dbv Technologies | Patches and uses thereof |
| US20040137004A1 (en) * | 2002-03-19 | 2004-07-15 | Glenn Gregory M | Patch for transcutaneous immunization |
| EP1608316A4 (de) * | 2003-03-24 | 2007-08-15 | Mercia Pharma Inc | Verfahren und zusammensetzungen zur behandlung und prävention von entzündlichen erkrankungen |
| KR20060096030A (ko) * | 2003-09-17 | 2006-09-05 | 베이비 부스트 인코퍼레이티드 | 알레르기 방지 방법 및 기구 |
| WO2007059979A2 (en) * | 2005-11-23 | 2007-05-31 | Universität Zürich | Allergy treatment by epicutaneous allergen administration |
| US8449894B2 (en) * | 2006-05-26 | 2013-05-28 | City Of Hope | Aspergillus vaccine preparation and methods of making and using thereof |
| JP5127208B2 (ja) * | 2006-08-24 | 2013-01-23 | 独立行政法人理化学研究所 | 組換えスギ花粉抗原融合遺伝子と可溶性産物の製造方法 |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| WO2009004900A1 (ja) * | 2007-06-29 | 2009-01-08 | Josai University Corporation | ユビキノン含有免疫アジュバント |
| FR2924349B1 (fr) | 2007-12-03 | 2010-01-01 | Dbv Tech | Methode de desensibilitation aux allergenes |
| FR2924350B1 (fr) | 2007-12-03 | 2010-08-13 | Dbv Tech | Procede et compositions pour la vaccination par voie cutanee |
| DE102008006394A1 (de) * | 2008-01-28 | 2009-07-30 | Beiersdorf Ag | Verwendung von Wirkstoffkomplexen aus Panthenol, Glycerin, Citrat und/oder Bisabolol gegen Pollenallergien |
| WO2010013350A1 (ja) | 2008-08-01 | 2010-02-04 | Ａｓｐｉｏｎ株式会社 | Ｓ／ｏ型経皮免疫剤 |
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| CN103249401B (zh) | 2010-09-15 | 2016-01-20 | 兰德尔·J·米斯尼 | 使用细菌毒素衍生的转运序列递送生物活性剂的系统和方法 |
| RU2690675C2 (ru) | 2012-08-21 | 2019-06-05 | Санофи Байотекнолоджи | Способы лечения или предотвращения астмы посредством введения антагониста il-4r |
| TWI697334B (zh) | 2013-06-04 | 2020-07-01 | 美商再生元醫藥公司 | 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| WO2015130975A1 (en) | 2014-02-28 | 2015-09-03 | Regeneron Pharmaceuticals, Inc. | Methods for treating skin infection by administering an il-4r antagonist |
| PT3139965T (pt) | 2014-05-07 | 2021-12-27 | Applied Molecular Transp Llc | Moléculas de fusão derivadas de toxinas cholix para administração oral de carga biologicamente ativa |
| MX2017006286A (es) | 2014-11-14 | 2018-01-23 | Sanofi Biotechnology | Metodos para tratar sinusitis cronica con polipos nasales por administracion de un antagonista de il-4r. |
| EP4442323A3 (de) | 2016-09-01 | 2025-01-01 | Regeneron Pharmaceuticals, Inc. | Verfahren zur prävention oder behandlung von allergien durch verabreichung eines il-4r-antagonisten |
| US10485844B2 (en) | 2016-09-22 | 2019-11-26 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor |
| US20180092983A1 (en) * | 2016-10-05 | 2018-04-05 | Tian Xin Wang | Methods and reagents to treat autoimmune diseases and allergy |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
| KR20250044796A (ko) | 2017-10-30 | 2025-04-01 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| MA52624A (fr) | 2018-05-13 | 2021-03-24 | Regeneron Pharma | Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r |
| DK3650037T3 (da) | 2018-11-07 | 2022-05-02 | Applied Molecular Transport Inc | Indgivelseskonstrukter til transcytose og tilhørende fremgangsmåder |
| PH12021552123A1 (en) | 2019-03-21 | 2022-08-22 | Regeneron Pharma | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| JP7592064B2 (ja) | 2019-07-16 | 2024-11-29 | サノフィ・バイオテクノロジー | Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法 |
| US11504426B2 (en) | 2019-08-05 | 2022-11-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist |
| AU2020326713A1 (en) | 2019-08-05 | 2022-02-17 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| MX2022001975A (es) | 2019-08-16 | 2022-03-11 | Applied Molecular Transport Inc | Composiciones, formulaciones y produccion y purificacion de interleucinas. |
| EP4417215A1 (de) * | 2023-02-20 | 2024-08-21 | Sorbonne Universite | Interleukin-1 zur behandlung und vorbeugung von allergien |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2227861B1 (de) * | 1973-05-04 | 1976-07-02 | Anvar | |
| US5980898A (en) * | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| US7097845B2 (en) * | 1997-04-23 | 2006-08-29 | Jacob Sten Petersen | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
| DE69936355T2 (de) * | 1998-02-25 | 2008-02-21 | The Government Of The United States, As Represented By The Secretary Of The Army | Verwendung von Hautpenetrationsförderern und für die Zerstörung der oberen Hautschichten geeigneten Mitteln zur Erhöhung der transkutanen Immunantwort |
| AU748565B2 (en) * | 1998-06-23 | 2002-06-06 | Board Of Trustees Of The Leland Stanford Junior University | Adjuvant therapy |
-
2002
- 2002-05-23 CA CA002447795A patent/CA2447795A1/en not_active Abandoned
- 2002-05-23 US US10/477,909 patent/US20050074462A1/en not_active Abandoned
- 2002-05-23 EP EP02751507A patent/EP1450855B1/de not_active Expired - Lifetime
- 2002-05-23 WO PCT/IB2002/003053 patent/WO2002093998A2/en not_active Ceased
- 2002-05-23 AT AT02751507T patent/ATE440617T1/de not_active IP Right Cessation
- 2002-05-23 AU AU2002339121A patent/AU2002339121B2/en not_active Ceased
- 2002-05-23 DE DE60233519T patent/DE60233519D1/de not_active Expired - Lifetime
- 2002-05-23 DK DK02751507T patent/DK1450855T3/da active
- 2002-05-23 JP JP2002590728A patent/JP4339598B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004536804A (ja) | 2004-12-09 |
| WO2002093998A9 (en) | 2005-05-26 |
| EP1450855B1 (de) | 2009-08-26 |
| EP1450855A2 (de) | 2004-09-01 |
| AU2002339121B2 (en) | 2007-03-22 |
| US20050074462A1 (en) | 2005-04-07 |
| WO2002093998A2 (en) | 2002-11-28 |
| DK1450855T3 (da) | 2010-01-11 |
| WO2002093998A3 (en) | 2004-06-03 |
| CA2447795A1 (en) | 2002-11-28 |
| DE60233519D1 (de) | 2009-10-08 |
| JP4339598B2 (ja) | 2009-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE440617T1 (de) | Unterdrückung von allergischen reaktionen durch transkutane verabreichung von allergenen zusammen mit oder fusioniert mit toxinuntereinheiten oder deren fragmenten | |
| DE60026584D1 (de) | Microbielles wirkstoffabgabesystem | |
| McNeela et al. | A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery | |
| WO2004016750A3 (en) | FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | |
| DE60141773D1 (de) | Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren | |
| EP4226938A3 (de) | Coronavirus-impfstoff | |
| BRPI0411784A (pt) | anticorpos contra interleucina -22 e usos para os mesmos | |
| IL211037A (en) | Antigen @ reactant @ with @ serum @ hyper | |
| BR0313492A (pt) | Formulação de anticorpos humanos para tratar distúrbios associados ao tnf-alfa | |
| BR0207283A (pt) | Anticorpos anti-egfr modificados com imunogenicidade reduzida | |
| WO2023147092A3 (en) | Coronavirus vaccine | |
| Baillie et al. | Characterization of the human immune response to the UK anthrax vaccine | |
| Gwinn et al. | A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen | |
| DK1471936T3 (da) | HIV-Vaccine og fremgangsmåde til anvendelse | |
| Gu et al. | Increased potency of BioThrax® anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109 | |
| DK0536302T3 (da) | Forbedrede adjuvanser og vacciner | |
| WO2023012652A3 (en) | Hypoallergenic peanut allergens, production and use thereof | |
| Pichler et al. | The fold variant BM4 is beneficial in a therapeutic Bet v 1 mouse model | |
| Moschos et al. | Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunisation | |
| ATE290081T1 (de) | Parietaria judaica ns-ltp-antigenvarianten, entsprechende pharmazeutische zusammensetzungen und ihre verwendung | |
| Tabatabaian et al. | Allergic rhinitis management: what’s next? | |
| Larsen et al. | Adjuvant effect of quaternary ammonium compounds in a murine model | |
| DE60233812D1 (de) | Konzentriertes x-ray kontrastmittel effektiv als universal antigen und zur verhütung oder vermeidung von allergischen reaktionen | |
| Yasuda et al. | Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies | |
| Datta et al. | The therapeutic potential of antigen‐oligonucleotide conjugates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |